UPDATE: Mizuho Securities Upgrades Cubist Pharmaceuticals to Buy, Raises PT on Pending Acquisitions of Optimer and Trius

Loading...
Loading...
In a report published Wednesday, Mizuho Securities analyst Mario Corso upgraded the rating on
Cubist PharmaceuticalsCBST
from Neutral to Buy, and raised the price target from $50.00 to $77.00. In the report, Mizuho Securities noted, “We are upgrading our rating on CBST shares to Buy from Neutral with a price target of $77 vs. $50 previously. We have added the pending acquisitions of Optimer and Trius to our financial models, deriving DCF valuations of $77, $96 and $51 in three different revenue/EPS scenarios. Catalysts for achieving our price target are the transactions closing/integration by year end 2013, CBST financial guidance in early 2014, CXA-201 Phase III data by year end, and FDA approval of tedizolid toward mid-2014.” Cubist Pharmaceuticals closed on Tuesday at $61.59.
Posted In: Analyst ColorUpgradesAnalyst RatingsMario CorsoMizuho Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...